Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMB-104
- Development stage
- Preclinical
- Lead developer
- IM Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
IMB-104 is a monoclonal antibody currently in the discovery or preclinical stage of development by IMBiologics, a South Korean biotechnology company. The candidate is engineered using the proprietary **ePENDY** (enhanced Potency and Extended half-life by Ne-binding and De-fucosylation) platform. This technology optimizes the antibody's Fc region to increase its affinity for the neonatal Fc receptor (FcRn) at acidic pH, thereby extending its circulating half-life, and utilizes afucosylation to enhance its binding to FcγRIIIa, which boosts effector functions such as antibody-dependent cellular cytotoxicity (ADCC). While the specific biological target of IMB-104 has not been publicly disclosed, it is positioned within the company's immunology pipeline for the treatment of autoimmune, inflammatory, and allergic diseases.
- Other names
- mAb-ePENDY
Beyond the preview
Go deeper on IMB-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMB-104.